Company: CERO
Filing Date: 2025-08-22
Form Type: 424B3
Source: 0001213900-25-080011
Chunk: 3

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 424B3
Chunk 3
---
 2.                        | Unregistered                                                                                                                         
 Sales of Equity Securities and Use of Proceeds                                                                                       |     |   45 |
| Item                      
 3.                        | Defaults                                                                                                                             
 Upon Senior Securities                                                                                                               |     |   45 |
| Item                      
 4.                        | Mine                                                                                                                                 
 Safety Disclosures                                                                                                                   |     |   45 |
| Item                      
 5.                        | Other                                                                                                                                
 Information                                                                                                                          |     |   45 |
| Item                      
 6.                        | Exhibits                                                                                                                             |     |   46 |
| SIGNATURES                |                                                                                                                                      |     |   48 |

<div align='center'>i

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</div>

This Quarterly Report on Form 10-Q (this “Quarterly Report”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations and financial position, business strategy, drug candidates, planned preclinical studies and clinical trials, results of preclinical studies, clinical trials, research and development (“R&D”) costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential,” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements contained in this Quarterly Report include, but are not limited to, statements about:

| ● | our                    
 financial performance; |

| ● | our ability to obtain additional cash and the sufficiency of our existing                                                              
 cash, cash equivalents and equity securities to fund our future operating expenses and capital expenditure requirements, including the 
 development and, if approved, commercialization of our product